HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.

Abstract
Current antipsychotics provide symptomatic relief for patients suffering from schizophrenia and related psychoses; however, their effectiveness is variable and many patients discontinue treatment due to side effects. Although the etiology of schizophrenia is still unclear, a leading hypothesis implicates an imbalanced dopaminergic system. Muscarinic acetylcholine (ACh) receptors regulate dopamine levels in key areas of the brain involved in psychosis, with the M(4) subtype emerging as a key regulator of dopaminergic hyperactivity. Unfortunately, no selective small molecule tools exist to provide pharmacological validation of this hypothesis. Here, we describe the discovery of a small molecule modulator, LY2033298, that is highly selective for human M(4) receptors by virtue of targeting an allosteric site on this receptor. Pharmacological assays confirmed the selectivity of LY2033298 for the M(4) receptor and revealed the highest degree of positive allosteric enhancement of ACh potency thus far identified. Radioligand binding assays also show this compound to directly potentiate agonist binding while having minimal effects on antagonist binding. Mutational analysis identified a key amino acid (D(432)) in the third extracellular loop of the human M(4) receptor to be critical for selectivity and agonist potentiation by LY2033298. Importantly, LY2033298 was active in animal models predictive of clinical antipsychotic drug efficacy indicating its potential use as a first-in-class, selective, allosteric muscarinic antipsychotic agent.
AuthorsW Y Chan, D L McKinzie, S Bose, S N Mitchell, J M Witkin, R C Thompson, A Christopoulos, S Lazareno, N J M Birdsall, F P Bymaster, C C Felder
JournalProceedings of the National Academy of Sciences of the United States of America (Proc Natl Acad Sci U S A) Vol. 105 Issue 31 Pg. 10978-83 (Aug 05 2008) ISSN: 1091-6490 [Electronic] United States
PMID18678919 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 3-amino-5-chloro-6-methoxy-4-methyl-thieno(2,3-b)pyridine-2-carboxylic acid cyclopropylamide
  • Antipsychotic Agents
  • Nicotinic Acids
  • Receptor, Muscarinic M4
  • Small Molecule Libraries
  • Thiophenes
Topics
  • Allosteric Regulation (drug effects)
  • Antipsychotic Agents (pharmacology, therapeutic use)
  • Cell Line
  • DNA Mutational Analysis
  • Humans
  • Nicotinic Acids (pharmacology)
  • Radioligand Assay
  • Receptor, Muscarinic M4 (genetics, metabolism)
  • Schizophrenia (drug therapy)
  • Signal Transduction (drug effects)
  • Small Molecule Libraries
  • Thiophenes (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: